Format

Send to

Choose Destination
Rev Med Inst Mex Seguro Soc. 2016 Jan-Feb;54(1):64-9.

[Indications for the use of continuous subcutaneous insulin infusion in pediatric patients with type 1 diabetes mellitus].

[Article in Spanish; Abstract available in Spanish from the publisher]

Author information

1
Facultad Mexicana de Medicina, Universidad La Salle, Distrito Federal, México. mario.rendon@imss.gob.mx.

Abstract

in English, Spanish

BACKGROUND:

Diabetes is a serious health problem for pediatrics. In pediatric patients control depends on correct insulin administration. The most usual is subcutaneous administration according to the glycemic control. The aim was to analyze the indications for continuous subcutaneous insulin infusion (CSII) in type 1 diabetes mellitus (T1DM) children and adolescents.

METHODS:

It was carried out a descriptive study in patients from 1 to 16 years with T1DM who underwent CSII therapy. The main cause to use this therapy was analyzed, and also if that cause was different regarding age, sex and disease progression.

RESULTS:

61 patients underwent CSII therapy. The median age at the beginning of treatment was 9 years old; 43 patients (71.6 %) had more than one year of diagnosis. The main reasons to use CSII were: 42.6 % had to improve their quality of life, 34.4 % had to reduce the high glycemic variability, 13.1 % had to control severe recurrent hypoglycemia, and 9.8 % had to control their HbA1c. For children under 6 years of age (n = 14) the more frequent indication were recurrent hypoglycemia and to improve their quality of life; children from 6 to 12 years of age (n = 27) had to improve their quality of life, and in children over 12 years CSII was indicated for high glycemic variability and severe recurrent hypoglycemia. There was no different indication related between sexes.

CONCLUSION:

Improve their quality of life and reach a better glycemic control were the main reasons to start CSII in our patients.

KEYWORDS:

Diabetes mellitus; Glycosylated hemoglobin A; Insulin infusion systems

PMID:
26820201
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center